Jenscare Scientific Valuation

Is 9877 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 9877 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 9877's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 9877's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 9877?

Key metric: As 9877 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 9877. This is calculated by dividing 9877's market cap by their current book value.
What is 9877's PB Ratio?
PB Ratio	1.1x
Book	CN¥1.08b
Market Cap	CN¥1.21b

9877 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-1.3x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 9877's PB Ratio compare to its peers?

The above table shows the PB ratio for 9877 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.6x
2407 Gaush Meditech	1x	n/a	HK$1.6b
1696 Sisram Medical	0.4x	26.5%	HK$1.6b
1358 PW Medtech Group	0.4x	n/a	HK$1.5b
2160 MicroPort CardioFlow Medtech	0.7x	102.9%	HK$1.7b
9877 Jenscare Scientific	1.1x	96.3%	HK$1.3b

Price-To-Book vs Peers: 9877 is expensive based on its Price-To-Book Ratio (1.1x) compared to the peer average (0.6x).

Price to Book Ratio vs Industry

How does 9877's PB Ratio compare vs other companies in the HK Medical Equipment Industry?

2 Companies	Price / Book	Estimated Growth	Market Cap
2216 Broncus Holding	0.2x	n/a	US$32.17m
2393 Yestar Healthcare Holdings	0.2x	n/a	US$20.67m

No more companies available in this PB range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 9877 is expensive based on its Price-To-Book Ratio (1.1x) compared to the Hong Kong Medical Equipment industry average (1.1x).

Price to Book Ratio vs Fair Ratio

What is 9877's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

9877 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	1.1x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 9877's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

OrbusNeich Medical Group Holdings

HK$3.1b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

6929

HK$3.78

-7.8%

-36.8%

Sinopharm Group

HK$63.3b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.30

1.2%

5.8%

Sisram Medical

HK$1.6b

Engages in the research, design, development, manufacture, and sales of medical aesthetics and dental equipment, home use devices, injectables, and cosmeceuticals products in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa.

1696

HK$3.38

6.6%

-34.7%